Human Vaccine Adjuvants Market Trends and Top Players 2020-2030
The human vaccine adjuvants market value is projected to grow from US$ 1,571.41 million in 2022 to US$ 4,489.23 million by 2030. The human vaccine adjuvants market is further anticipated to record a CAGR of 14.0% from 2022 to 2030.
Increasing demand for personalized vacccines to improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders are likely to remain key trends in the market.
Human Vaccine Adjuvants Market Analysis
Human Vaccine adjuvants market is driven by the growing focus on immunization globally followed by the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. HIV, Hepatitis A, B, C, and HPV are some of the common communicable diseases which cen be prevented with the help of vaccinations. However, growing pharmaceutical industry is expected to develop new adjuvants along with vaccines which is likely to create ample opportunities in the coming years. Furthermore, rising trend of personalized vaccines has increased the collaboration among research institutes and increased the R&D activities which is expected to amplfy the market growth during forecast period.
Human Vaccine Adjuvants Market Overview
Human Vaccine adjuvants market is driven by the growing focus on immunization globally followed by the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. HIV, Hepatitis A, B, C, and HPV are some of the common communicable disease which cen be prevented with the help of vaccinations. Additionally, North America accounts for the major market share in 2022 owing to the increasing incidence of infectious diseases, increasing healthcare expenditure, and the presence of major market players. Asia Pacific is anticipated to grow with the highest CAGR in the coming years owing to the high prevalence of infectious diseases and initiatives by the government to provide free vaccinations through immunization programs in Asia Pacific countries.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Human Vaccine Adjuvants Market: Strategic Insights
Market Size Value in US$ 1,571.41 million in 2022 Market Size Value by US$ 4,489.23 million by 2030 Growth rate CAGR of 14.0% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Human Vaccine Adjuvants Market: Strategic Insights
| Market Size Value in | US$ 1,571.41 million in 2022 |
| Market Size Value by | US$ 4,489.23 million by 2030 |
| Growth rate | CAGR of 14.0% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Human Vaccine Adjuvants Market Drivers and Opportunities
Growing focus on Immunization to Favor Market
Governments of various nations recognize the importance of vaccination as a cost-effective strategy to prevent and control chronic diseases. According to the WHO, immunization currently prevents 3.5–5 million deaths yearly from diseases such as diphtheria, tetanus, pertussis, influenza, and measles. As a result, governments in various nations are implementing immunization programs to reduce the incidence of diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. These programs often target specific populations, such as children, older people, and high-risk individuals, to ensure they are adequately protected against these chronic conditions. The US, India, and Australia are among the key prominent nations that have effective immunization programs. For example, the US has the Vaccines for Children (VFC) program, which became operational in 1994 and is funded by the federal government. Similarly, India has the Universal Immunization Programme (UIP), which targets immunization of 26.7 million newborns and 29 million pregnant women annually. The United Nations International Children's Emergency Fund (UNICEF) also offers an immunization program that provides vaccines to protect children from life-threatening diseases globally.
Growing Pharmaceutical Industry Create Lucrative Growth Opportunities
The US has one of the most R&D-intensive pharmaceutical industries globally. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the North America market (US and Canada) remained the world's largest market with a 49.1% share, well ahead of Europe, China, and Japan. The US is the global leader in innovative R&D investments, and the country produced over half of the world's new molecules in the last decade. Additionally, as per EFPIA, in 2021, North America accounted for 49.1% of global pharmaceutical sales, compared with 23.4% for Europe.
Similarly, according to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016–2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the human vaccine adjuvants market in the coming years.
Human Vaccine Adjuvants Market Report Segmentation Analysis
Key segments that contributed to the derivation of the Human vaccine adjuvants market analysis are type, application, and end user.
- Based on type, the Human vaccine adjuvants market is segmented into emulsion adjuvants, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment held a largest market share in 2022.
- By application, the market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022.
- In terms of end user, the market is classified into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held a largest share of the market in 2022.
Human Vaccine Adjuvants Market Share Analysis by Geography
The geographic scope of the Human vaccine adjuvants market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the market and the US held the largest share of the market in 2022. The market in the country is projected to grow significantly during the forecast period owing to factors such as an increase in the incidence of infectious diseases, increasing healthcare expenditure, and the presence of major market players. According to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the nation's GDP. As per the US Department of Health & Human Services, national health spending is expected to grow at an annual rate of 5.4% from 2019–2028, reaching US$ 6.2 trillion by 2028. The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants. Asia Pacific is anticipated to grow with the highest CAGR in the coming years owing to the high prevalence of infectious diseases and initiatives by the government to provide free vaccinations through immunization programs in Asia Pacific countries.
Human Vaccine Adjuvants Market Report Scope
Human Vaccine Adjuvants Market News and Recent Developments
The Human vaccine adjuvants market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the Human vaccine adjuvants market are listed below:
- SPI Pharma Inc collaborated with Q-Vant Biosciences Inc this partnership combines Q-Vant's technology with SPI global reach and services. The arrangement includes investment in the expansion of Q-Vant’s proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations. (Source: SPI Pharma, Newsletter, October 2023)
- Croda International Plc partnered with Amyris and Botanical Solutions Inc (BSI) for for the supply of biotechnology-derived, pharmaceutical grade squalene used in adjuvants to boost immune responses and to produce a sustainable pharmaceutical grade QS-21 vaccine adjuvant which enable the production of next generation adjuvant systems for new vaccine development respectively. (Source: Croda International Plc, Newsletter, May 2023)
- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium (MCDC) requirement 22-05, "Adjuvant Activity to Vaccines Prototype," a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks, Inc. and SaponiQx, Inc. to discover and develop next-generation vaccine adjuvants. This will require to use a combination of high-throughput empirical and artificial intelligence/machine learning approaches, including Generative Molecular Design (GMD), to develop superior novel saponin-based adjuvants.( Ginkgo Bioworks, Inc., Press Release, February 2024)
Human Vaccine Adjuvants Market Report Coverage and Deliverables
The “Human Vaccine Adjuvants Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
- Human vaccine adjuvants market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Human vaccine adjuvants market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Human vaccine adjuvants market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Human vaccine adjuvants market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Application, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Growing focus on immunization globally followed by the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. HIV, Hepatitis A, B, C, and HPV are some of the common communicable disease which cen be prevented with the help of vaccinations are the driving factors impacting the Human vaccine adjuvants market
North America dominated the Human vaccine adjuvants market in 2023
Increasing demand for personalized vacccines to improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders are the future trends of the Human vaccine adjuvants.
The estimated value of the Human vaccine adjuvants market by 2031 is US$ 5.16 Bn
The expected CAGR of the Human vaccine adjuvants market is 14.3%
The leading players operating in the Human vaccine adjuvants market includes Novartis AG, Dynavax Technologies Corp, CSL Ltd, SEPPIC SA, SPI Pharma Inc, Hawaii Biotech Inc, Croda International Plc, Novavax Inc, Phibro Animal Health Corp, Creative Biolabs Inc among others
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Human Vaccine Adjuvants Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Human Vaccine Adjuvants Market – Key Market Dynamics
5.1 Human Vaccine Adjuvants Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Prevalence of Chronic Diseases
5.2.2 Growing Focus on Immunization Programs
5.3 Market Restraints
5.3.1 Manufacturing Complexities and Regulatory Challenges
5.4 Market Opportunities
5.4.1 Growing Pharmaceutical Industry
5.5 Future Trends
5.5.1 Rising Trend of Personalized Vaccines
5.6 Impact of Drivers and Restraints:
6. Human Vaccine Adjuvants Market – Global Market Analysis
6.1 Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 – 2030
6.2 Human Vaccine Adjuvants Market Forecast Analysis
7. Human Vaccine Adjuvants Market Analysis – by Type
7.1 Particulate Adjuvant
7.1.1 Overview
7.1.2 Particulate Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Emulsion Adjuvant
7.2.1 Overview
7.2.2 Emulsion Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.3 Combination Adjuvant
7.3.1 Overview
7.3.2 Combination Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. Human Vaccine Adjuvants Market Analysis – by Application
8.1 Influenza
8.1.1 Overview
8.1.2 Influenza: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.2 Hepatitis
8.2.1 Overview
8.2.2 Hepatitis: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Human papilloma virus (HPV)
8.3.1 Overview
8.3.2 Human papilloma virus (HPV): Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9. Human Vaccine Adjuvants Market Analysis – by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2 CMOs and CROs
9.2.1 Overview
9.2.2 CMOs and CROs: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10. Human Vaccine Adjuvants Market – Geographical Analysis
10.1 Overview
10.2 North America
10.2.1 North America Human Vaccine Adjuvants Market Overview
10.2.2 North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.2.3 North America: Human Vaccine Adjuvants Market Breakdown, by Type
10.2.3.1 North America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
10.2.4 North America: Human Vaccine Adjuvants Market Breakdown, by Application
10.2.4.1 North America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Application
10.2.5 North America: Human Vaccine Adjuvants Market Breakdown, by End User
10.2.5.1 North America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by End User
10.2.6 North America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.2.6.1 North America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.2.6.2 United States: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.2.6.2.1 United States: Human Vaccine Adjuvants Market Breakdown, by Type
10.2.6.2.2 United States: Human Vaccine Adjuvants Market Breakdown, by Application
10.2.6.2.3 United States: Human Vaccine Adjuvants Market Breakdown, by End User
10.2.6.3 Canada: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.2.6.3.1 Canada: Human Vaccine Adjuvants Market Breakdown, by Type
10.2.6.3.2 Canada: Human Vaccine Adjuvants Market Breakdown, by Application
10.2.6.3.3 Canada: Human Vaccine Adjuvants Market Breakdown, by End User
10.2.6.4 Mexico: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.2.6.4.1 Mexico: Human Vaccine Adjuvants Market Breakdown, by Type
10.2.6.4.2 Mexico: Human Vaccine Adjuvants Market Breakdown, by Application
10.2.6.4.3 Mexico: Human Vaccine Adjuvants Market Breakdown, by End User
10.3 Europe
10.3.1 Europe Human Vaccine Adjuvants Market Overview
10.3.2 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.3 Europe: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.3.1 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
10.3.4 Europe: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.4.1 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Application
10.3.5 Europe: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.5.1 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by End User
10.3.6 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.3.6.1 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.3.6.2 Germany: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.2.1 Germany: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.2.2 Germany: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.2.3 Germany: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.6.3 United Kingdom: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.3.1 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.3.2 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.3.3 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.6.4 France: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.4.1 France: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.4.2 France: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.4.3 France: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.6.5 Italy: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.5.1 Italy: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.5.2 Italy: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.5.3 Italy: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.6.6 Spain: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.6.1 Spain: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.6.2 Spain: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.6.3 Spain: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.6.7 Rest of Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.7.1 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.7.2 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.7.3 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by End User
10.4 Asia Pacific
10.4.1 Asia Pacific Human Vaccine Adjuvants Market Overview
10.4.2 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.3 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.3.1 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
10.4.4 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.4.1 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Application
10.4.5 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.5.1 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by End User
10.4.6 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.4.6.1 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.4.6.2 China: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.2.1 China: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.2.2 China: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.2.3 China: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.6.3 Japan: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.3.1 Japan: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.3.2 Japan: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.3.3 Japan: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.6.4 India: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.4.1 India: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.4.2 India: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.4.3 India: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.6.5 Australia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.5.1 Australia: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.5.2 Australia: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.5.3 Australia: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.6.6 South Korea: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.6.1 South Korea: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.6.2 South Korea: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.6.3 South Korea: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.6.7 Rest of APAC: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.7.1 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.7.2 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.7.3 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by End User
10.5 Middle East and Africa
10.5.1 Middle East and Africa Human Vaccine Adjuvants Market Overview
10.5.2 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.5.3 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
10.5.3.1 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
10.5.4 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
10.5.4.1 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Application
10.5.5 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
10.5.5.1 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by End User
10.5.6 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.5.6.1 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.5.6.2 Saudi Arabia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.5.6.2.1 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Type
10.5.6.2.2 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Application
10.5.6.2.3 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by End User
10.5.6.3 South Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.5.6.3.1 South Africa: Human Vaccine Adjuvants Market Breakdown, by Type
10.5.6.3.2 South Africa: Human Vaccine Adjuvants Market Breakdown, by Application
10.5.6.3.3 South Africa: Human Vaccine Adjuvants Market Breakdown, by End User
10.5.6.4 United Arab Emirates: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.5.6.4.1 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Type
10.5.6.4.2 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Application
10.5.6.4.3 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by End User
10.5.6.5 Rest of Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.5.6.5.1 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
10.5.6.5.2 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
10.5.6.5.3 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
10.6 South and Central America
10.6.1 South and Central America Human Vaccine Adjuvants Market Overview
10.6.2 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 | (US$ Million)
10.6.3 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
10.6.3.1 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
10.6.4 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
10.6.4.1 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Application
10.6.5 South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User
10.6.5.1 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by End User
10.6.6 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.6.6.1 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.6.6.2 Brazil: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.6.6.2.1 Brazil: Human Vaccine Adjuvants Market Breakdown, by Type
10.6.6.2.2 Brazil: Human Vaccine Adjuvants Market Breakdown, by Application
10.6.6.2.3 Brazil: Human Vaccine Adjuvants Market Breakdown, by End User
10.6.6.3 Argentina: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.6.6.3.1 Argentina: Human Vaccine Adjuvants Market Breakdown, by Type
10.6.6.3.2 Argentina: Human Vaccine Adjuvants Market Breakdown, by Application
10.6.6.3.3 Argentina: Human Vaccine Adjuvants Market Breakdown, by End User
10.6.6.4 Rest of South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.6.6.4.1 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
10.6.6.4.2 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
10.6.6.4.3 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User
11. Industry Landscape
11.1 Overview
12. Company Profiles
12.1 Novartis AG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Dynavax Technologies Corp
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 CSL Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Seppic SA
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 SPI Pharma Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Hawaii Biotech Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Croda International Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Novavax Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Phibro Animal Health Corp
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Creative Biolabs Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
List of Tables
Table 1. Human Vaccine Adjuvants Market Segmentation
Table 2. Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Table 3. Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Type
Table 4. Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Application
Table 5. Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by End User
Table 6. North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 8. North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 9. North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 10. United States: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 11. United States: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 12. United States: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 13. Canada: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 14. Canada: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 15. Canada: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 16. Mexico: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 17. Mexico: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 18. Mexico: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 19. Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 20. Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 21. Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 22. Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 23. Germany: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 24. Germany: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 25. Germany: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 26. United Kingdom: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 27. United Kingdom: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 28. United Kingdom: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 29. France: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 30. France: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 31. France: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 32. Italy: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 33. Italy: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 34. Italy: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 35. Spain: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 36. Spain: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 37. Spain: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 38. Rest of Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 39. Rest of Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 40. Rest of Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 41. Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 42. Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 43. Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 44. Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 45. China: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 46. China: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 47. China: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 48. Japan: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 49. Japan: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 50. Japan: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 51. India: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 52. India: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 53. India: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 54. Australia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 55. Australia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 56. Australia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 57. South Korea: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 58. South Korea: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 59. South Korea: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 60. Rest of APAC: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 61. Rest of APAC: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 62. Rest of APAC: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 63. Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 64. Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 65. Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 66. Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 67. Saudi Arabia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 68. Saudi Arabia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 69. Saudi Arabia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 70. South Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 71. South Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 72. South Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 73. United Arab Emirates: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 74. United Arab Emirates: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 75. United Arab Emirates: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 76. Rest of Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 77. Rest of Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 78. Rest of Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 79. South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 80. South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 81. South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 82. South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 83. Brazil: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 84. Brazil: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 85. Brazil: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 86. Argentina: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 87. Argentina: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 88. Argentina: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 89. Rest of South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Type
Table 90. Rest of South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 91. Rest of South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by End User
Table 92. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 93. Glossary of Terms, Global Human Vaccine Adjuvants Market
List of Figures
Figure 1. Human Vaccine Adjuvants Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Human Vaccine Adjuvants Market Breakdown by Geography, 2022 and 2030 (%)
Figure 5. Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 – 2030
Figure 6. Human Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 7. Particulate Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Emulsion Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Combination Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Human Vaccine Adjuvants Market Share (%) – by Application (2022 and 2030)
Figure 12. Influenza: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Hepatitis: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Human papilloma virus (HPV): Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Human Vaccine Adjuvants Market Share (%) – by End User (2022 and 2030)
Figure 17. Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. CMOs and CROs: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Human Vaccine Adjuvants Market Breakdown by Region, 2022 and 2030 (%)
Figure 21. North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 22. North America: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
Figure 23. North America: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
Figure 24. North America: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
Figure 25. North America: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 26. United States: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 27. Canada: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 28. Mexico: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 29. Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 30. Europe: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
Figure 31. Europe: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
Figure 32. Europe: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
Figure 33. Europe: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 34. Germany: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 35. United Kingdom: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 36. France: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 37. Italy: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 38. Spain: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 39. Rest of Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 40. Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 41. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
Figure 42. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
Figure 43. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
Figure 44. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 45. China: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 46. Japan: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 47. India: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 48. Australia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 49. South Korea: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 50. Rest of APAC: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 51. Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 52. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
Figure 53. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
Figure 54. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
Figure 55. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 56. Saudi Arabia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 57. South Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 58. United Arab Emirates: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 59. Rest of Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 60. South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 61. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
Figure 62. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
Figure 63. South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
Figure 64. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 65. Brazil: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 66. Argentina: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 67. Rest of South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For